OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SY
So-Young International Inc.
There isn't enough reported data to score SY yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
SY's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SY PE Valuation
SY has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SY Forward outlook
There aren't enough analyst estimates for SY to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SY on earnings quality, reporting a profit while its opponent remains loss making.
SY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.28 | +$0.46 |
| Q1 2026 | -$0.29 | +$0.39 |
| Q4 2025 | -$0.27 | +$0.39 |
| Q3 2025 | -$0.84 | -2200% |
| Q2 2025 | -$0.74 | -1950% |
| Q1 2025 | -$0.68 | -6900% |
| Q4 2024 | -$0.66 | -3400% |
| Q3 2024 | $0.04 | 0% |
SY lost $0.28 per share over the past year, a smaller loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SY on profitability, with a higher operating margin.
SY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $75.6M | +33% |
| Q1 2026 | $64.6M | +45% |
| Q4 2025 | $68.2M | +23% |
| Q3 2025 | $58M | +4% |
| Q2 2025 | $56.8M | -7% |
| Q1 2025 | $44.6M | -6.6% |
| Q4 2024 | $55.4M | -5.5% |
| Q3 2024 | $55.8M | -3.5% |
SY's revenue has grown year over year for four quarters in a row: $76M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -8.6% | +3.8 points |
| Q1 2026 | -13% | +1.2 points |
| Q4 2025 | -22% | +140 points |
| Q3 2025 | -19% | -20 points |
| Q2 2025 | -12% | -14 points |
| Q1 2025 | -15% | -3 points |
| Q4 2024 | -162% | -161 points |
| Q3 2024 | 1.3% | +1.8 points |
SY's operating margin was −8.6% last quarter, up 3.8 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with SY at down 1,200%.
SY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $0 | $0 |
| Q4 2025 | -$45.3M | -$45.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
SY's free cash flow was −$45M over the past year, against $0 the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +187K shares |
| 1 year | -0.1% | -75.7K shares |
| 3 years | +0.6% | +796K shares |
| 5 years | -6.3% | -8.9M shares |
| Available history | -6.2% | -8.6M shares |
SY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | $2.3M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -73.4x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -4.1x | Net Cash |
| Q1 2024 | -6.3x | Net Cash |
| Q4 2023 | -5.1x | Net Cash |
| Q3 2023 | -5.3x | Net Cash |
| Q2 2023 | -17.6x | Net Cash |
| Q1 2023 | -141.9x | Net Cash |
SY has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 12.9 | Oversold |
SY's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SY PE vs Healthcare Sector
| Metric | SY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SY has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SY on trend strength, trading above more of its moving averages.
SY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.29 | 15% below |
| 20 week MA | $2.22 | 13% below |
| 50 week MA | $2.50 | 22% below |
| 100 week MA | $2.35 | 17% below |
| 200 week MA | $1.88 | 3.2% above |
SY has fallen below most of its moving averages, though it's still 3.2% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SY on returns for 2026, with the stronger performance.
SY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $11.4 | -4.4% |
| 2021 | $11.4 | $3.13 | -73% |
| 2022 | $3.13 | $1.39 | -56% |
| 2023 | $1.39 | $1.29 | -7.2% |
| 2024 | $1.29 | $0.82 | -36% |
| 2025 | $0.82 | $2.63 | +221% |
| 2026 YTD | $2.63 | $1.94 | -26% |
SY's yearly returns have swung widely, from +221% in 2025 to −73% in 2021. It's down 26% so far in 2026.